Arbutus Biopharma Corporation
ABUS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $36 | $26 | $31 | $109 |
| Short-Term Investments | $86 | $100 | $116 | $46 |
| Receivables | $2 | $2 | $1 | $1 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $2 | $4 | $3 | $4 |
| Total Curr. Assets | $127 | $132 | $151 | $161 |
| Property Plant & Equip (Net) | $4 | $6 | $7 | $8 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $6 | $37 | $36 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $4 | $12 | $44 | $44 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $132 | $144 | $195 | $204 |
| Liabilities | – | – | – | – |
| Payables | $2 | $3 | $4 | $3 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $8 | $12 | $16 | $0 |
| Other Curr. Liab. | $5 | $7 | $13 | $8 |
| Total Curr. Liab. | $16 | $22 | $33 | $11 |
| LT Debt | $1 | $8 | $12 | $19 |
| Deferred Rev, NC | $3 | $0 | $6 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $15 | $8 | $8 | $5 |
| Total NC Liab. | $19 | $16 | $26 | $24 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $1 | $2 | $2 | $3 |
| Total Liabilities | $34 | $38 | $59 | $35 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $1,410 | $1,350 | $1,319 | $1,287 |
| Retained Earnings | -$1,347 | -$1,277 | -$1,204 | -$1,134 |
| AOCI | -$48 | -$48 | -$50 | -$48 |
| Other Equity | $82 | $81 | $72 | $65 |
| Total Equity | $97 | $106 | $137 | $169 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $132 | $144 | $195 | $204 |
| Net Debt | -$35 | -$18 | -$18 | -$90 |